scispace - formally typeset
R

Richard Camplejohn

Researcher at King's College London

Publications -  48
Citations -  3387

Richard Camplejohn is an academic researcher from King's College London. The author has contributed to research in topics: Breast cancer & Mutation. The author has an hindex of 27, co-authored 48 publications receiving 3336 citations. Previous affiliations of Richard Camplejohn include St Thomas' Hospital.

Papers
More filters
Journal ArticleDOI

Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: An index of cell proliferation with evidence of deregulated expression in some, neoplasms

TL;DR: Data suggest that in normal tissues and lymphoid neoplasms, PCNA immunolocalization can be used as an index of cell proliferation, however, in some forms of neoplasia, including breast and gastric cancer and in vitro cell lines, the simple relation between PCNA expression and cell proliferation is lost.
Journal ArticleDOI

Generation of an anti‐tumour immune response in a non‐immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1‐like profile of intratumoural cytokine expression

TL;DR: Data show that B16/HSVtk+ cells die predominantly by necrosis, rather than apoptosis, on exposure to GC, a process which may be associated with the generation of anti‐tumour inflammatory responses, and discuss the development of improved vectors for gene therapy to augment these effects in vivo.
Journal ArticleDOI

Overexpression of the c-erbB-2 oncoprotein: Why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?

TL;DR: Although in pure DCIS c-erbB-2 positively appears to be associated with tumours with a greater invasive potential, and c- Derbyshire negativity with tumour having a more favourable prognosis, the latter is not necessarily true in infiltrating disease.
Journal ArticleDOI

The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer.

TL;DR: Multivariate analysis showed that c-erbB-2 staining and SPF gave independent information on RFS for women with node positive disease.
Journal ArticleDOI

Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry.

TL;DR: The impact of tumor size, histologic grade, estrogen receptor status, ER status, tumor ploidy, and S-phase fraction on relapse-free survival (RFS) for 169 patients with node-negative breast cancer is examined in order to identify groups of patients at high and low risk of relapse.